Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q3 2015 · 10-Q
Revenue$164.94M$164.94M+19.6% vs Q3 2014 Net Income$36.94M$36.94M+69.2% vs Q3 2014 EPS Diluted$0.79$0.79+61.2% vs Q3 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived$104,759,000+32.7% Free Cash Flowderived$90,809,000+23.2% Margins · derivedGross margin38.3%
Operating margin38.3%+15.8 pt vs Q3 2014
Net margin22.4%+6.6 pt vs Q3 2014
ended Sep 30, 2015 · filed Nov 6, 2015 · 37 d after period end